ELEDON PHARMACEUTICALS INC (ELDN) Fundamental Analysis & Valuation

NASDAQ:ELDN • US28617K1016

Current stock price

2.85 USD
-0.15 (-5%)
At close:
2.98 USD
+0.13 (+4.56%)
After Hours:

This ELDN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ELDN Profitability Analysis

1.1 Basic Checks

  • ELDN had negative earnings in the past year.
  • ELDN had a negative operating cash flow in the past year.
  • In the past 5 years ELDN always reported negative net income.
  • In the past 5 years ELDN always reported negative operating cash flow.
ELDN Yearly Net Income VS EBIT VS OCF VS FCFELDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of ELDN (-7.83%) is better than 84.33% of its industry peers.
  • Looking at the Return On Equity, with a value of -11.17%, ELDN belongs to the top of the industry, outperforming 86.27% of the companies in the same industry.
Industry RankSector Rank
ROA -7.83%
ROE -11.17%
ROIC N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ELDN Yearly ROA, ROE, ROICELDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELDN Yearly Profit, Operating, Gross MarginsELDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ELDN Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELDN Yearly Shares OutstandingELDN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ELDN Yearly Total Debt VS Total AssetsELDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.17, we must say that ELDN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.17, ELDN perfoms like the industry average, outperforming 48.55% of the companies in the same industry.
  • There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.17
ROIC/WACCN/A
WACCN/A
ELDN Yearly LT Debt VS Equity VS FCFELDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 6.74 indicates that ELDN has no problem at all paying its short term obligations.
  • ELDN has a Current ratio of 6.74. This is in the better half of the industry: ELDN outperforms 67.31% of its industry peers.
  • ELDN has a Quick Ratio of 6.74. This indicates that ELDN is financially healthy and has no problem in meeting its short term obligations.
  • ELDN has a Quick ratio of 6.74. This is in the better half of the industry: ELDN outperforms 67.31% of its industry peers.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74
ELDN Yearly Current Assets VS Current LiabilitesELDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ELDN Growth Analysis

3.1 Past

  • ELDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.48%, which is quite impressive.
EPS 1Y (TTM)50.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ELDN will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.02% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-73.6%
EPS Next 2Y-31.13%
EPS Next 3Y-25.6%
EPS Next 5Y-11.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELDN Yearly Revenue VS EstimatesELDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M
ELDN Yearly EPS VS EstimatesELDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

0

4. ELDN Valuation Analysis

4.1 Price/Earnings Ratio

  • ELDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ELDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELDN Price Earnings VS Forward Price EarningsELDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELDN Per share dataELDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • A cheap valuation may be justified as ELDN's earnings are expected to decrease with -25.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.13%
EPS Next 3Y-25.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ELDN Dividend Analysis

5.1 Amount

  • ELDN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELDN Fundamentals: All Metrics, Ratios and Statistics

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (3/19/2026, 8:00:02 PM)

After market: 2.98 +0.13 (+4.56%)

2.85

-0.15 (-5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)N/A
Inst Owners54.6%
Inst Owner Change20.49%
Ins Owners0.06%
Ins Owner Change9.66%
Market Cap225.83M
Revenue(TTM)N/A
Net Income(TTM)-10.17M
Analysts84.62
Price Target8.16 (186.32%)
Short Float %8.24%
Short Ratio7.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.12%
Min EPS beat(2)17.65%
Max EPS beat(2)44.59%
EPS beat(4)4
Avg EPS beat(4)110.73%
Min EPS beat(4)17.65%
Max EPS beat(4)306.56%
EPS beat(8)7
Avg EPS beat(8)29.64%
EPS beat(12)10
Avg EPS beat(12)21.49%
EPS beat(16)13
Avg EPS beat(16)17.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.48
P/tB 3.85
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS1.15
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.83%
ROE -11.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z -2.17
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.93%
EPS Next Y-73.6%
EPS Next 2Y-31.13%
EPS Next 3Y-25.6%
EPS Next 5Y-11.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.63%
OCF growth 3YN/A
OCF growth 5YN/A

ELEDON PHARMACEUTICALS INC / ELDN Fundamental Analysis FAQ

What is the fundamental rating for ELDN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELDN.


What is the valuation status for ELDN stock?

ChartMill assigns a valuation rating of 3 / 10 to ELEDON PHARMACEUTICALS INC (ELDN). This can be considered as Overvalued.


What is the profitability of ELDN stock?

ELEDON PHARMACEUTICALS INC (ELDN) has a profitability rating of 2 / 10.


Can you provide the financial health for ELDN stock?

The financial health rating of ELEDON PHARMACEUTICALS INC (ELDN) is 7 / 10.